Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $566 million, down 6% year-over-year, but down only 2% when excluding write-offs [17][18] - Adjusted EBITDA was $250 million with a margin of 44.2%, slightly lower than expected due to revenue mix and elevated health insurance costs [9][18] - For the full year 2025, total revenue was $2.28 billion, and Adjusted EBITDA was $971 million at a margin of 42.6% [18] Business Line Data and Key Metrics Changes - Revenue from modular products was effectively flat year-over-year, indicating stabilization in the lease portfolio [8] - Portable storage leasing revenue decreased by approximately $10 million year-over-year, driven by lower volumes [19] - VAPS revenue was flat year-over-year, with penetration increasing to 17.8% of total revenue [20] Market Data and Key Metrics Changes - Modular pending order book was up 17% year-over-year, driven by large RFP wins in enterprise accounts [12] - Order rates for portable storage products increased by 11% year-over-year, primarily from RFP wins [13] - The company expects an additional 2,000 units of demand related to the upcoming World Cup in Q2 and Q3 [12] Company Strategy and Development Direction - The company is focused on returning to steady organic growth and has implemented a multi-year continuous improvement roadmap [6][10] - Key initiatives include enhancing local market execution, developing enterprise accounts, and expanding value-added offerings [6][11] - The network optimization plan aims to exit surplus real estate and reduce occupancy costs, expected to save $25 million to $30 million annually [24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about returning to growth, with a conservative outlook for 2026 that does not assume improvement in business trends [10][28] - The company is seeing early results from initiatives that could lead to positive organic revenue growth in the second half of 2026 [10][33] - Management highlighted improvements in sales staffing and local market execution as key drivers for future performance [10][11] Other Important Information - The company returned $151 million to shareholders through repurchases and dividends in 2025 [22] - Total debt at the end of 2025 was under $3.6 billion, with a leverage ratio of 3.6x [23] - The company recognized a non-cash restructuring charge of $302 million from accelerated depreciation on rental equipment [24] Q&A Session Summary Question: Inquiry about order book trends and sustainability - Management noted that seasonal activity typically picks up in Q1 and early Q2, with larger RFP wins driving current momentum [37][40] Question: Clarification on VAPS momentum - Management indicated that VAPS penetration is increasing due to a mix shift and traction in the modular portfolio, with ongoing initiatives to improve performance [42][43] Question: Understanding modular orders and backlog - Management expects a sizable portion of the pending order book to convert in the first half of the year, but is cautious about extrapolating trends into the second half [49] Question: Free cash flow guidance for 2026 - Management provided a guidance of approximately $415 million for Adjusted Free Cash Flow, excluding costs related to the network optimization plan [50][51] Question: Drivers of enterprise revenue growth - Management clarified that enterprise revenue growth is primarily volume-driven, with no significant pricing differences between segments [58] Question: Impact of staffing changes on order growth - Management indicated that recent changes in the sales organization are beginning to yield positive results, contributing to order and activation growth [60][61] Question: Trends in portable storage rates - Management noted that average rates for portable storage are up 9% year-over-year, driven by a favorable mix shift towards cold storage offerings [67][68]

Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to $804 million, marking its third consecutive year of double-digit revenue growth [17][19] - EBITDA improved by 25% to $216 million, driven by strong demand for Illuccix and the launch of Gleolan [19][23] - The gross margin remained stable at 53%, with a significant portion of gross margin generated from the precision medicine business [22][23] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional $113 million [19][23] - The precision medicine business generated approximately $400 million in gross margin, with 94% of the gross margin coming from this segment [20][23] - Investments in product development totaled $157 million, focusing on late-stage pipeline projects [22] Market Data and Key Metrics Changes - The precision medicine portfolio delivered $622 million in revenue, with sequential growth every quarter, even during challenging market conditions [30] - The company is expanding its market presence, with Illuccix now available in 17 countries and marketing authorizations in over 24 markets [35] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investments ranging from $200 million to $240 million in 2026 [26] - A dual product strategy for Illuccix and Gleolan is in place to manage economic needs and reimbursement preferences effectively [58][60] - The company is focused on expanding its product offerings, indications, and geographical reach, particularly in key markets like the U.K., Germany, and China [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving approximately 20% revenue growth in 2026, with guidance set at $950 million to $970 million [28][29] - The company is committed to reinvesting earnings into R&D and commercial growth rather than optimizing near-term earnings per share [68] - Management highlighted the importance of clinical credibility and operational reliability in sustaining market leadership [32][33] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials expected to generate significant data this year [47] - The ProstACT Global study is progressing well, with recruitment for part two ramping up [48][49] Q&A Session Questions and Answers Question: When might we see data for 591, the safety data? - The company is completing clinical case report forms and will disclose the data simultaneously with the FDA submission, with no delays expected from the FDA side [54][56] Question: Can you elaborate on the early performance of the two-product strategy for Illuccix and Gleolan? - The two-product strategy allows the company to manage economic needs and reimbursement preferences effectively, adapting to changes in the reimbursement environment [58][60] Question: Will the company reinvest earnings to achieve close to zero NPAT for F-26, F-27, and F-28? - The company will reinvest the majority of earnings back into R&D and commercial growth, with no profit objective for the next two years [68] Question: How much growth in precision medicine revenue is coming from markets outside of the U.S.? - Currently, 95% of revenue is U.S.-based, but the company expects this mix to change as it expands into other markets like Japan [74]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $566 million, down 6% year-over-year, but adjusted for write-offs, the decline was 2% [17][18] - Adjusted EBITDA was $250 million with a margin of 44.2%, slightly lower than expected due to revenue mix and elevated health insurance costs [9][18] - For the full year 2025, total revenue was $2.28 billion, and adjusted EBITDA was $971 million at a margin of 42.6% [18][20] Business Line Data and Key Metrics Changes - Modular products revenue was effectively flat year-over-year, indicating stabilization in the lease portfolio [8][19] - Portable storage leasing revenue decreased by approximately $10 million year-over-year, driven by lower volumes [19] - VAPS revenue was flat year-over-year, with penetration increasing to 17.8% of total revenue [20] Market Data and Key Metrics Changes - The modular pending order book increased by 17% year-over-year, driven by large RFP wins in enterprise accounts [12] - Order rates for portable storage products were up 11% year-over-year, primarily from enterprise account wins [13] - The company expects additional demand related to the upcoming World Cup, estimating 2,000 units in Q2 and Q3 [12] Company Strategy and Development Direction - The company is focused on returning to steady organic growth and has implemented a multi-year continuous improvement roadmap [6][10] - Strategic initiatives include enhancing local market execution, developing enterprise accounts, and expanding value-added offerings [6][11] - The network optimization plan aims to exit surplus real estate and reduce occupancy costs, with expected annual savings of $25 million to $30 million [24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about returning to growth, with a conservative outlook for 2026 that does not assume improvement in business trends [10][28] - The company is seeing early results from initiatives that could lead to positive organic revenue growth in the second half of 2026 [10][33] - Management highlighted improvements in sales staffing and local market execution as key drivers for future performance [10][11] Other Important Information - The company ended 2025 with total debt under $3.6 billion and a leverage ratio of 3.6x [23] - Adjusted free cash flow for Q4 was $91 million, with a full-year total of $489 million, exceeding guidance [20][22] - The company recognized a non-cash restructuring charge of $302 million in Q4 due to accelerated depreciation on rental equipment [24] Q&A Session Summary Question: Order book trends and sustainability - Management noted that while there are encouraging signs in the order book, it is too early to extrapolate these trends into the second half of the year [36][41] Question: VAPS momentum and changes - Management acknowledged slight increases in VAPS penetration but emphasized the need for further improvement and expansion of offerings [42][43] Question: Modular orders and backlog conversion - Management expects a significant portion of the pending order book to convert in the first half of the year, but remains cautious about extrapolating activity levels [48][49] Question: Free cash flow guidance - The company anticipates around $415 million of adjusted free cash flow for 2026, excluding costs related to the network optimization plan [50][51] Question: Enterprise revenue growth drivers - Management indicated that enterprise revenue growth is primarily volume-driven, with no significant pricing differences compared to other customer segments [57][58] Question: Local customer sentiment and subcontracted business - Management reported improved sentiment among local customers and highlighted progress in winning subcontracted work through a new rewards program [78][80]

Financial Data and Key Metrics Changes - In Q4 2025, Newmont generated $2.8 billion in free cash flow, contributing to a total of $7.3 billion for the full year, marking record earnings and free cash flow on both a quarterly and annual basis [9] - The company achieved a 4% increase in its quarterly common dividend, reflecting a commitment to enhance shareholder returns [7] - General and Administrative (G&A) costs were improved by $100 million, equating to a 21% improvement for 2026 [9] Business Line Data and Key Metrics Changes - Newmont produced 5.7 million ounces of gold, 28 million ounces of silver, and 135,000 tons of copper from its core portfolio in 2025 [8] - The company achieved commercial production at Ahafo North, contributing over 300,000 ounces of gold production in 2025 [9] Market Data and Key Metrics Changes - The gold reserve base stands at 180 million ounces, with an additional 149 million ounces of gold resource, representing approximately 40 years of production life [12] - The reserve price assumption for 2025 was increased from $1,700 per ounce to $2,000 per ounce, remaining conservative compared to the three-year trailing average [12][13] Company Strategy and Development Direction - Newmont's strategy focuses on safety, efficiency, operational consistency, and enhancing shareholder returns through predictable capital returns [4][5] - The company is advancing a mine life extension program at Lihir and completing a feasibility study for the Red Chris block cave [11] - The capital allocation framework prioritizes sustaining capital and dividends, with excess cash allocated to share repurchases [33][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a volatile macroeconomic environment while focusing on disciplined investment and long-term value creation [38] - The company anticipates a production trough in 2026 due to planned mine sequencing, with a return to growth expected in 2027 [25][31] Other Important Information - An investigation is underway following a fatal incident at the Tanami operation, emphasizing the company's commitment to safety [8] - Newmont's exploration program is focused on near-mine and brownfields opportunities, with promising results at Brucejack and Ahafo South [16][18] Q&A Session Summary Question: CapEx and potential upside through Red Chris and Merian - Management confirmed that capital guidance remains at $1.1 billion for sustaining capital and $1.3 billion for development capital, with updates on Red Chris expected later in the year [41][43] Question: Long-term growth targets of six million ounces - Management indicated that better guidance on achieving the six million ounces target will be provided towards the end of the year [49] Question: M&A views and current gold price environment - Management expressed satisfaction with the current asset portfolio and emphasized a disciplined approach to evaluating potential M&A opportunities [51] Question: Capital allocation and buyback commitments - Management confirmed that excess cash would be returned to shareholders through buybacks, with a disciplined approach to capital allocation [54][55] Question: Nevada Gold Mines performance and maximizing shareholder value - Management highlighted ongoing discussions with JV partners to improve performance and maximize shareholder value [60][61] Question: Cost guidance and inflation drivers - Management noted that costs attributable to sales have remained constant year on year, with significant cost savings initiatives contributing to a $100 per ounce reduction in costs [72][74]

Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to AUD 804 million, marking its third consecutive year of double-digit revenue growth [18][20] - EBITDA improved by 25% to AUD 216 million, driven by strong demand for Illuccix and the launch of Gozellix [20][23] - The gross margin remained stable at 53%, with 94% of gross margin generated from the precision medicine business [21][22] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional AUD 113 million [20][23] - The precision medicine business demonstrated a 28% increase in operating profit and a 25% increase in EBITDA [23] - The company invested AUD 157 million into product development, focusing on its late-stage pipeline [22] Market Data and Key Metrics Changes - The precision medicine portfolio generated AUD 622 million in revenue, up 22% year-over-year, with sequential growth every quarter [31] - Illuccix is now available in 17 countries with reimbursement secured, and marketing authorizations in over 24 markets [35] - The company anticipates a 25% growth in its precision medicine business for 2026, driven by the full year of RLS revenue [28] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investment in the range of AUD 200 million to AUD 240 million for 2026 [26] - The focus will remain on reinvesting revenues back into the business rather than optimizing near-term earnings per share [26][72] - The company is committed to building long-term value through disciplined capital allocation and strategic investments in R&D and commercial performance [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of roughly 20%+ revenue growth in 2026, with guidance set at AUD 950 million to AUD 970 million [28][30] - The company is focused on executing its strategic plan to grow the precision medicine business by expanding product offerings and geographic reach [35] - Management acknowledged the challenges faced with regulatory approvals but emphasized the importance of learning from these experiences to enhance future submissions [15][72] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials highlighted as priorities for the year [49] - The ProstACT Global study is currently recruiting for part two, with results expected to be released soon [50] - The company has made extensive changes to its management team and regulatory affairs capabilities to improve future product submissions [15] Q&A Session Summary Question: When might data for 591 be available? - Management indicated that the company is not waiting on the FDA and will disclose data as soon as it is available [56][58] Question: Insights on the two-product strategy for Illuccix and Gozellix? - The two-product strategy allows the company to manage economic needs and preferences of different customer types, adapting to changes in reimbursement environments [61][62] Question: Clarification on reinvesting earnings for future years? - Management confirmed that the majority of earnings will be reinvested back into the company for growth, particularly in R&D and commercial development [72] Question: Growth contribution from markets outside the US? - Currently, 95% of revenue is US-based, but the company expects this mix to change as it expands into other markets [78] Question: Will R&D spending be adjusted based on commercial performance? - Management stated that R&D investment is discretionary and can be adjusted based on commercial performance, focusing on priority studies [75][76]

Financial Data and Key Metrics Changes - In Q4 2025, Newmont generated $2.8 billion in free cash flow, contributing to a total of $7.3 billion for the full year, marking record earnings and free cash flow on both a quarterly and annual basis [9] - The company achieved a 4% increase in its quarterly common dividend, reflecting a commitment to enhancing shareholder returns [7] - General and administrative (G&A) costs were improved by $100 million, equating to a 21% improvement for 2026 [9] Business Line Data and Key Metrics Changes - Newmont produced 5.7 million ounces of gold, 28 million ounces of silver, and 135,000 tons of copper from its core portfolio in 2025 [8] - The successful completion of the non-core divestiture program generated $4.5 billion in proceeds, with $3.4 billion returned to shareholders through dividends and share repurchases [9] Market Data and Key Metrics Changes - The gold reserve base stands at 180 million ounces, with an additional 149 million ounces of gold resource, representing approximately 40 years of production life [12] - The reserve price assumption for 2025 was increased from $1,700 per ounce to $2,000 per ounce, remaining conservative compared to the three-year trailing average [12][13] Company Strategy and Development Direction - The company is focused on safety, efficiency, operational consistency, and enhancing shareholder returns through predictable capital returns [5][4] - Newmont is advancing a mine life extension program at Lihir and completing a feasibility study for the Red Chris block cave [11][21] - The capital allocation framework prioritizes sustaining capital and dividends, followed by development capital and share repurchases [33][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a volatile macroeconomic environment while focusing on operational delivery and financial resilience [5][39] - The company anticipates a production trough in 2026 due to planned mine sequencing, with a return to production growth expected in 2027 [25][31] Other Important Information - An investigation is underway following a fatal incident at the Tanami operation, emphasizing the company's commitment to safety [8] - The company is actively pursuing exploration opportunities, particularly at Brucejack and Ahafo South, with expectations of adding significant new gold reserves [17][18] Q&A Session Summary Question: CapEx and potential upside through Red Chris and Merian - Management confirmed that capital guidance remains on track, with updates on Red Chris expected in the second half of the year [44] Question: Discussions with Nevada Gold Mines joint venture partner - Management indicated ongoing discussions focused on improving performance at Nevada Gold Mines [46] Question: Long-term growth targets of 6 million ounces - Management stated that better guidance on achieving the long-term growth target will be provided towards the end of the year [50] Question: M&A opportunities in the current gold price environment - Management expressed satisfaction with the current asset portfolio and indicated that any potential changes would be made in a disciplined manner [52] Question: Capital allocation and buyback commitments - Management confirmed that excess cash would be returned to shareholders through buybacks, with a disciplined approach to capital allocation [56] Question: Cost guidance and inflation drivers - Management noted that costs attributable to sales have remained constant year on year, with significant cost savings initiatives contributing to a reduction in all-in sustaining costs [59][74] Question: Maximizing shareholder value at Nevada Gold Mines - Management highlighted the importance of understanding district potential and optimizing plans across the portfolio to maximize shareholder value [61]

Copart (NasdaqGS:CPRT) Q2 2026 Earnings call February 19, 2026 05:30 PM ET Company ParticipantsJeff Liaw - CEOLeah Stearns - CFOConference Call ParticipantsBob Labick - Equity Research AnalystBret Jordan - Equity Research AnalystCraig Kennison - Equity Research AnalystJash Patwa - Equity Research AnalystJeff Lick - Equity Research AnalystJohn Healy - Equity Research AnalystOperatorGood day, everyone, and welcome to the Copart Incorporated second quarter fiscal 2026 earnings call. Just a reminder, today's co ...

Copart (NasdaqGS:CPRT) Q2 2026 Earnings call February 19, 2026 05:30 PM ET Company ParticipantsJeff Liaw - CEOLeah Stearns - CFOConference Call ParticipantsBob Labick - Equity Research AnalystBret Jordan - Equity Research AnalystCraig Kennison - Equity Research AnalystJash Patwa - Equity Research AnalystJeff Lick - Equity Research AnalystJohn Healy - Equity Research AnalystOperatorGood day, everyone, and welcome to the Copart Incorporated second quarter fiscal 2026 earnings call. Just a reminder, today's co ...

Telix Pharmaceuticals (NasdaqGS:TLX) H2 2025 Earnings call February 19, 2026 05:30 PM ET Speaker13Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Kyahn Williamson, SVP of Investor Relations and Corporate Communications. Please go ahead.Speaker9Thank you, and thank you to everybody for joining us on this call this morning, this evening, wherever you are in the world. We launched our annual report and full year results on the ASX ...

WillScot Mobile Mini (NasdaqCM:WSC) Q4 2025 Earnings call February 19, 2026 05:30 PM ET Speaker7Welcome to the fourth quarter 2025 WillScot Earnings Conference Call. My name is Cherie, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded. I will now turn the call over to Charlie Woolutter. Charlie, you may begin.Speaker2All right. Thank you, Charlie. Goo ...